Uro-ginecology

5

Utipro® Plus Launched In France

We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.

Read more

Utipro® Plus Launched In Israel

We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections. Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017. Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)

Read more

New scientific communication on UTIPRO® PLUS

Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73, the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago de Compostela 5-8 Sept 2017. The results confirm the non-pharmacological barrier effect of xyloglucan and its utility in the prevention of urinary tract infections.

Read more

Let's meet in..

2021, Mar 01

euroPLX 75 Lisbon

Read more